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Abstract 
Although often mentioned as an area in which Product-Service-Systems (PSS) possess great 
potential, the health care sector has not been in the focus of research in the past. This paper briefly 
reviews the challenges and benefits of implementing PSS and analyses the special characteristics 
of the health care market. A case study is then reported in which a PSS approach has been 
developed for a business-to-business, as well as a business-to-customer, scenario, in order to 
establish and then grow a market for an innovative method to treat brain tumours and 
neurodegenerative diseases. 
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1 Introduction 
This paper presents a case study of an application of PSS to health care.  It starts 
with a summary of the challenges and benefits of the adoption of PSS, and a 
summary of available design methodologies for PSS.  Special characteristics of 
the health care market are then discussed. Finally, a health care case study is 
presented, centring on convection-enhanced delivery of therapeutic agents. 
1.1. Challenges and Benefits of Implementing Product 
Service Systems 
Despite the great potential of PSS and several very successful implementations in 
the industrial sector, there is still a certain resistance for a broader adoption of the 
concept [1, 2]. Putting PSS into practise requires a completely new mindset for 
both the company providing the PSS and the customer using the offered PSS [3]. 
A company developing a PSS needs to be ready to adopt the concept [4]. This 
adoption may include changes in organization and a significant investment of 
money and time [1]. Companies which have implemented a matrix organization 
are more like to adopt and successfully implement PSS [2].  
Three major functions within a company face major impacts if the decision is 
made to offer PSS to a customer rather than simply a tangible product.  
Firstly, the research and development (R&D) function has to gain the resources 
and the knowledge to be able to offer value adding services in combination with a 
product. R&D is also required to obtain the technical knowledge regarding the 
product and its constant quality improvement [5].  
In addition, R&D efforts are not complete after the product launch. PSS providers 
increase their responsibility over the whole life cycle of a product, from 
development, through its use, including constant improvement, to the step of 
discarding and recycling. This influences development priorities. Ideally it moves 
designers towards a greater focus on developing more durable and recyclable 
products, as they may also be re-used in a PSS for other customers, or be 
reconfigured or updated by varying the services associated with the product [6]. 
Secondly, as the relationship between customers and the company changes 
dramatically with the implementation of PSS, a company’s marketing group is 
likely to be faced with process redesign [5].   
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As PSS are inherently streamlining efforts towards the fulfilment of the final use 
for the customer, a different approach is necessary to collect requirements. In 
traditional product design, the design input consists of requirements for the 
product as evaluated by the marketing function. Instead of collecting this 
information, marketing needs to gather detailed knowledge about the final use for 
the customer, considering that customers may be more keen on paying for the use 
or the result, rather than for the operation of a product or the ownership of the 
product itself [7]. 
This approach requires a new mindset of the actors within and outside of a 
company. In order to collect the right data to constantly improve the PSS, the 
organization and communication infrastructure has to be set up to facilitate 
exchange between actors during the development phase and also during the 
performance phase of the product [2, 4]. 
This is the most crucial part for a positive adoption of the offering. In order to 
optimize and customize the PSS, users have to be involved early in the 
development phase to ensure the correct definition of the needs [4].  
Thirdly, human capital gains importance when a producing manufacturer is 
enhancing products by integrating service components. Consequently human 
resource development is the third major function within a PSS providing company 
that is heavily affected [4].   
For companies, PSS clearly can set the basis of improved design and quality as 
well as continuous innovation, which can be the strategic approach towards cost-
pressure and increased competition in a global market [3].  
PSS allows adding value to a product that may be hard for competitors to imitate. 
Especially in mature markets, adding value often is the only way to secure and 
further improve the market position of a company. Successfully implementing 
these changes, however, is not a guarantee of success with PSS. Besides the 
readiness of the company, customers need to be ready to accept such a concept 
[4]. Cultural or social barriers to the implementation of a PSS may exist.  For 
example, end users may not feel comfortable with their lack of ownership of the 
tangible product, which they require to fulfil their needs. In order for customers to 
provide the required input for designing and enhancing PSS, processes training of 
those customers would almost certainly be required [4]. However, willingness to 
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accept such training implies that the customer requires an initial level of 
acceptance of the concept.  
However there can also be clear advantages for the customer. Customers take 
advantage of better design and quality. Customized products may lead to higher 
degree of satisfaction with regards to their final needs. The changed ownership 
structures can also be counted as another benefit for the user. Despite some 
resistance to this concept, customers in general profit form paying for the use or - 
even more advantageous - the result. This takes away all responsibilities in terms 
of operation, availability, maintenance, insurance and recycling from the customer 
[4]. 
1.2. Designing Product Service Systems 
The focus of a PSS on the final use for the customer, rather than the requirements 
of a product suitable to be used to fulfil such final use, change the development 
processes away from those used for traditional product development 
Tan et al. [7] analyzed the status of research with regards to development 
methodologies for PSS and identified a research gap for such methodologies.  
In the absence of dedicated design methodologies, most methods for designing 
PSS are derived from traditional product development. Instead of approaching the 
design of PSS with a “green-field mindset” [3] often industry tends to design 
systems using current practise in product design. This inherent limitation may be 
the reason for the restricted adoption of PSS in industry.[2].  
PSS is adding complexity in terms of design. In fact it is adding new dimensions 
to the development process [6], since it is not sufficient to solve a problem 
defined by some design input requirements. In addition to this technological 
aspect, one needs to take in account the social as well as the cultural component. 
An understanding of the mindset of involved actors (such as users, and providers) 
is crucial to the design of a sophisticated PSS.  
Considering this complexity, PSS designers require methodologies and tools to 
visualize the network of actors and their needs. The same is true for the graphical 
representation of immaterial components versus tangible products. Such 
visualisation allows to better understand relations and to manage the different 
phases of design.  
5 
PSS are complex systems having implications in technology, human resources, 
marketing, customer relations and communication, so it appears reasonable to 
derive a design methodology for PSS from involved disciplines, such as social 
studies, marketing, management, engineering and information science [6]. 
Nevertheless, those methodologies are not taking in account all aspects of PSS 
and may form a barrier for further innovation.  
By analysing case studies, Morelli [6] proposed a generic design process in seven 
steps (see Table 1): 
Table 1: Generic PSS design process proposed by Morelli   
Design step Description 
Definition of value proposition Definition of the final needs of the end user 
Market analysis  Outline of the market players and the network between those players 
Product/Service definition Definition of the architecture and functionalities of the system 
Use-case analysis  Analysis of several conditions of use to define functions, requirements 
and priorities  
Tentative architecture PSS prototype development  
Test PSS prototype testing 
Final definition  Refinement of the tentative architecture based on test results 
 
Within each of these steps for PSS design, more specific tools could then be 
applied to generate a best outcome.     
2 The Health Care Market 
2.1. Special Characteristics of the Health Care Market 
More than any other market the health care sector is regulated.  This regulation is 
defined by governmental authorities but also by the industry itself, to mitigate the 
high risks often associated with development of drugs or medical devices.    
Considering the actors within this market, different layers of can be identified. 
These are summarised in Figure 1. Firstly, there are “framework defining” 
institutions, such as regulatory authorities and governmental, as well as private, 
health insurance companies.  
The layer of “technology providing” companies consists of pharmaceutical 
companies as well as software and hardware providers. Those companies provide 
products, services and combinations thereof to different users. Due to the 
specialization in medical health care, those users most likely will consist of 
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specialized physicians along the diagnostic and therapeutic workflow (e.g. 
radiologists for diagnosis, medical oncologists, radiotherapists and surgeons for 
treatment of cancer). The patients as “end user” form the basic layer of actors in 
the market, creating the actual need for a specific diagnostic or therapeutic 
procedure.  
Figure 1: Actors in the health care market 
 
 
Considering the potentially high risks, regulatory bodies require a proof of safety 
and efficacy to be documented by the approval-requesting company in order to 
approve the marketing of drugs, medial devices or services. Compliance to all 
applicable regulatory standards is mandatory for any provider of products or 
services to enter the market
1
.  
Governmental regulatory authorities like the Food and Drug Administration 
(FDA) in the United States influence development costs for drugs, medical 
devices or services by setting the standards, requirements and restrictions for 
R&D. Governmental authorities can also shift the focus of R&D within 
companies by special regulations, An example of this is an accelerated approval 
process for technology to treat “orphan diseases” (e.g. rare diseases with small 
                                                 
1 http://www.fda.gov/cdrh/ 
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patient population) , if the unmet medical need is higher than the incentive of the 
market [8]. Therefore, governmental policies clearly influence the market and its 
players in the health care sector.  
Insurance programs and companies play another major role in defining the 
framework of the market. Governmental health care insurance programs such as 
MEDICARE in the U.S. steer the market by their reimbursement policies. Besides 
the proof of safety and efficacy, those institutions also require additional 
information of the costs and benefits resulting from the adoption of a new 
treatment approach, compared to “standard care”.  
The reimbursement of drugs and procedures has a direct impact on the R&D 
strategy of technology providers. Studies showed that pharmaceutical companies 
tend to directly reinvest revenue into new R&D programs (Smith and Summers). 
The drug pricing set by MEDICARE or other payors affects the expected revenue 
and therefore has an impact on amount of money invested in R&D and as a 
consequence on the timelines of development programs. 
Pharmaceutical companies as well as medical device companies are driven by 
market incentives and primarily try to maximize their return on invest. Those 
companies usually have to manage significant risks during the R&D phases of a 
drug.  
The development process is divided into pre-clinical and clinical phases. The ratio 
of drug candidates entering the first clinical (human) phase and the succeeding 
therapeutics actually entering the market is only slightly above 10 to 1 in the 
treatment field of central nervous system (CNS) and only little higher in other 
areas [9].  
Time to market usually has a direct impact on the revenue of pharmaceutical 
companies. Potential products are usually first protected in a patent and then 
further developed to enter the market. Therefore, shorter the development time, 
the longer is the monopolistic period on the market, which leads to significantly 
higher profitability of the drug.  
Health care providers such as physicians primarily have the goal to treat patents in 
the best possible way. This group of players in the market can be a huge resource 
for the industry in R&D as well as marketing. Based on their specialized medical 
knowledge and their experience in daily clinical routine, physicians are the 
biggest source of new ideas.  
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Once those ideas are taken up by the industry, physicians are facilitating the 
creation of the mandatory data for verification and validation of new products. As 
a reward for this support, physicians can improve their standing as part of the 
research community (e.g. by publishing results about new treatment technologies). 
Being the experts and opinion leaders in their specific field of research, they also 
have the potential of being a marketing and lobbying resource for pharmaceutical 
or medical device companies, educating colleagues, but also regulatory authorities 
and insurance companies, on advantages of new products.  
Patients as the inner core of the market initially create the medical need. In the 
past, they played a quite passive role in the market, but due to better availability 
and transparency within the health care market, patients may now actively decide 
on which physician or institution they choose. Having better access to information 
about latest developments, patients also want to be part of the treatment decisions 
and stimulate health care providers to constantly improve quality of care.  
Derived from the individual goals of each actor, dependencies between such 
actors can be identified (see Table 2). Those dependences need to be considered in 
PSS design.
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Table 2: Goals and dependencies of actors in the health care market 
 Regulatory Authorities Insurance Companies Pharmaceutical Industry Medical Device Industry Health Care Provider Patient 
Regulatory 
authorities 
N/A  
Proof of safety 
Proof of efficacy 
Documentation 
QM-System 
Proof of safety 
Proof of efficacy 
Documentation 
QM-System 
Improved safety and 
efficacy 
Minimal impact on daily 
life 
N/A 
 
Insurance 
companies 
Reliable and independent 
analysis of safety and 
efficacy 
N/A 
Documented regulat.  
approval 
Proof of cost efficacy 
Documented regulat.  
approval 
Proof of cost efficacy 
High quality of care 
Standardization 
Cost efficacy 
Compliance to treatment 
 
 
Pharmaceutic
al Industry 
 
Guidelines for R&D 
Accelerated procedures 
Reimbursement codes for 
agents 
N/A 
Tailored devices and 
technologies 
Simplicity 
Consultation 
Input/Feedback 
Participate in trials 
Acceptance of approved 
drugs 
Participate in trials 
Medical 
Device 
Industry  
 
Guidelines for R&D 
Accelerated procedures 
 
Reimbursement codes for 
procedures 
Consultation 
Knowledge about mode of 
action 
N/A 
Input/Feedback 
Verification & Validation 
Publications 
Acceptance of treatment 
procedures 
 
Health care 
provider 
(physicians) 
 
Reliable review of safety 
and efficacy of drugs and 
devices 
Reimbursement for 
treatment procedures and 
drug prescriptions 
Innovations 
Appreciation of feedback 
and consultation 
Innovations 
Appreciation of feedback 
Easy to use devices 
N/A 
Compliance to treatment 
 
Patient 
 
 
Reliable review of safety 
and efficacy of drugs and 
devices 
Working reimbursement 
procedures 
 
Improved safety and 
efficacy 
Minimal side-effects 
 
Improved safety and 
efficacy 
Minimal impact on daily 
life 
Provision of best possible 
treatment 
Education (disease and 
treatment) 
N/A 
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2.2. Product Service Systems in Health Care 
The health care sector is frequently mentioned in PSS research to be one of the 
areas where the combination of tangible products and intangible services appears 
to offer great opportunity for innovation and improvement [4].  However, actual 
case studies are lacking in the literature.   
Nevertheless, the health care sector is facing the same trends towards servitization 
as other industry sectors, – in some cases to an even higher degree.  Therefore, it 
appears appropriate to analyse the specific implications for this sector.  
Despite the lack of academic research, big medical device companies like General 
Electric Medical Systems were eager to adopt PSS concepts at an early stage [10]. 
This strategic transition, however, proved to be a formidable challenge even for 
such big, well managed companies.  
As in other industry sectors, globalisation and its secondary effects have its 
impact on players in the health care sector.  Being in a much more competitive 
market, the need to differentiate becomes increasingly crucial.  
Spending on health care, projected to be 16,2% of the growth domestic product 
(GDP) in the United States (2007), has grown consistently faster than the overall 
economy since the 1960s [11].  However, owing to this explosion of costs in 
health care, the pressure to reduce cost can be considered to be significantly 
higher than in other areas.  
The medical sector, being one of the most innovative segments, is facing an 
accelerating trend to specialization. Since knowledge rapidly increases and 
diagnosis as well as treatment gets more and more patient specific, the whole 
network of actors is gaining complexity.  
“Integration” therefore becomes a significant value proposition, which, however, 
often is a multi-dimensional challenge.  The integration of a product into a, for 
example clinical, workflow is one of those dimensions, often requiring additional 
services such as consulting, training and education.  
Another integration is that of products into other tangible products. Those 
products may not only include devices but also combinations of drugs and 
devices, where malfunctions of the whole systems have to be eliminated.  
Last but not least, products (e.g. operating rooms) may need to be integrated into, 
for example hospital, infrastructure for optimal usage.  
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Considering these dimensions, clinicians, chemists, biologists, software and IT 
specialists, mechanical engineers, civil engineers, and even architects may be 
involved in such integration processes. This increasing need of integration 
outlines a huge potential for service components and PSS in this market. 
Another clear benefit of PSS in heath care is the close relationship to the user. The 
communication between, for example, a developer of medical devices and the end 
user, namely the physician - probably focused on certain specialties, for example, 
neurosurgery - faces fundamental difficulties due to the different knowledge 
background of actors and the different terminologies. A well defined PSS, 
including a close relationship between developer and customer, facilitates the 
knowledge transfer and constantly improves the communication between these 
groups. This ultimately will improve the quality of the provided PSS.  
At the same time, medical knowledge is crucial in many cases to actually define 
requirements and restrictions and to identify the final need for the user. Therefore, 
a close cooperation between the user and R&D is the key to enhance health care.  
By constantly collecting data about usage, as it is often implemented in PSS, and 
by taking customer feedback into account, sustainability can be achieved in this 
sector as the quality of medical devices enhances the quality of care.  
Product service systems may allow establishing new market segments by offering 
tailored solutions to a customer’s need. As the market evolves, such PSS may be 
modified to address new customer groups or new market scenarios.  
However, the readiness to adopt new procedures, technologies and services may 
significantly be reduced by a risk-adverse behaviour of each of the actors.  
Even in highly research driven and innovative areas such as the health care sector, 
there is a significant barrier for innovations to be taken up by the market, and 
replace the current “golden standard” of care, owing to the common goal of all 
actors to minimize their risk. PSS may enable pioneers to enhance their products 
by complementary service offerings suitable to address this issue. 
Supplementary services, for example user training, user monitoring and according 
retraining, as well as retrospective analysis of usage, allows to minimize the risk 
considered to be associated with new products and procedures. While training and 
consulting services often have a direct impact on the risk profile, other services in 
PSS are designed to generate data for further improvement to mitigate indirectly 
the risks. For product innovations, additional service components can open up the 
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market by creating user acceptance. Added services increase the confidence in 
using new technologies and therefore PSS can reach a certain threshold of security 
in opening a market, while an innovative product on its own may not reach this 
level of user acceptance.  
From PSS provider points of view, this decreases economic risks associated with 
innovative developments, since the combination of products and services may 
enhance the market penetration and increase the user base. 
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3. Case Study: Convection-Enhanced Delivery 
3.1. Methodology and Sectoral-Relevance of the Case 
Study 
The seven-step methodology suggested by Morelli (see section 1.3) has been 
followed in this case study for the definition of value proposition, a market 
analysis, the product/service definition and a use-case analysis.  
Especially for the business-to-business PSS, the testing phase, followed by the 
final definition, is replaced by individual discussions with contract partners (in 
this case pharmaceutical companies). Instead of having the market challenging the 
system, the PSS has to be individually tailored to a specific customer. In this case 
study only the generic part of the development is reported.  
Major parts of the business-to-business model outlined in the presented case study 
have been applied in a collaboration between pharmaceutical company A and 
medical device company B (see Table 3) to carry out an multinational clinical 
trial. This initial model was then modified based on a retrospective analysis of the 
collaboration. The enhanced model has been validated in several expert 
discussions, between medical device company B and pharmaceutical companies 
similar to pharmaceutical company A with regards to business relevant variables.  
The business-to-customer model has been developed based on expert discussions between 
pharmaceutical company A and medical device company B, validated in 
subsequent expert discussions between medical device company B and 
pharmaceutical companies substantially similar to pharmaceutical company A. 
Table 3: Details on companies involved in the case study 
Company Investor structure No. of employees 
Pharmaceutical company A Public traded 10-500 
Medical device company B privately held  500-1000 
 
 
The following case study refers to direct, convection-enhanced delivery of 
therapeutic agents into brain tissue to treat aggressive brain tumours or 
neurodegenerative diseases.  
This innovative treatment method requires a highly interdisciplinary approach to 
transfer it from research to market [12]. As the treatment includes drugs as well as 
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several medical devices, results of this case study should widely be applicable for 
the more generic, emerging segment of drug-device combinations.  
This combination of drugs and medical devices is a recent trend in the health care 
sector [13]. This is particularly true for the field of local delivery, which 
necessitates that pharmaceutical companies and medical device manufacturers to 
work jointly on the research and development issues [14]. In contrast to systemic 
delivery of therapeutics, where drugs are given by pills or intravenous injection, 
local drug delivery allows the drug to be placed exactly at the location in the body 
where it is needed. This leads to a high therapeutic concentration at the target, 
while the systemic concentration in the body is relatively low, causing less side 
effects and toxicity.  
Regulatory authorities like the Food & Drug Administration (FDA) are also 
addressing this trend by establishing guidelines [15]. Accordingly, the European 
Commission has also published guidelines for combined devices [16].   
3.2. Technological Background 
Despite impressive advances in medicine, the treatment of diseases related to the 
brain such as certain types of aggressive brain tumours and many 
neurodegenerative diseases still presents one of the biggest areas of unmet 
medical need. This is mainly due to the fact that the brain is protected by the 
“blood brain barrier” (BBB), which prevents it from being damaged or poisoned 
by substances in the human blood stream. While being vital for healthy people, 
this barrier becomes a major obstacle for the treatment of many diseases affecting 
the central nervous system (CNS). Promising drugs for the treatment of primary 
brain tumours such as Glioblasoma mulitforme (GBM) or neurodegenerative 
diseases such as Parkinson’s, Alzheimer’s, Multiple Sclerosis (MS), and epilepsy 
have failed in human trials over the last decades, although these drugs showed 
great potential in preclinical studies [17, 18]. Those disappointing results are most 
likely derived from the fact that the drug molecules never reached their target 
within the brain [17].  
Convection-enhanced delivery (CED) is a promising approach to circumvent the 
BBB. The drug is delivered directly to the target site within the brain tissue, by 
placing a catheter into the clinical target and applying a positive pressure gradient 
to push the drug into the tissue. In practice, this approach, which is superficially 
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simple, has been found to be highly complex, since the distribution of the drug is 
heavily depending on patient specific anatomical structures and pathology. 
Planning therefore is a very crucial part of the procedure and the technique 
requires a multidisciplinary approach to achieve significant improvement of the 
patient outcome.  
From a technological perspective a tailored system of a safe and effective drug, a 
patient specific treatment planning system and a dedicated set of devices (such as 
catheters and pumps) is necessary to ensure the delivery of the correct drug in the 
correct concentration to the correct target area in a defined period of infusion. The 
state of the art in this area is represented by catheter systems that promote 
convection-enhanced diffusion as the infusion mode. Additionally, users, in this 
case the relevant health-care professionals, need to be trained in the usage of the 
software and hardware tools provided in order to use them in the most optimum 
manner.   
An overview of the system is as follows. Several magnetic resonance (MR) image 
series of the patient’s brain are acquired for planning purposes.  These scans are 
loaded into a planning software tool in order to plan the exact locations of the 
drug target and entry points of catheters placed into the target tissue. This 
planning must be based on the patient specific imaging data as it has to take in 
account the individual anatomy and pathology of the patient.  
The main target of this pre-operational planning is to make sure that a convective 
flow is established within the solid tissue of the brain and that no drug leaks into 
the cerebrospinal fluid (CSF) compartment. Secondly, a maximum coverage of 
the previously defined clinical target volume is the goal of the planning exercise.  
Once the treatment plan is finalized, the required data needs to be transferred to 
the operating room (OR).  
The neurosurgeon will then place the catheters according to the plan using the 
planning data for navigational purposes. Once all catheters are in place and are 
connected to the infusion pumps containing the drug, the patient will be scanned 
again to verify the actual position of the catheters.  
For infusion, the patient will be hospitalized for several days to allow the whole 
drug volume to enter the patient at the required low, constant flow rate. During 
and after the infusion there may be several control scans to monitor the treatment.  
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3.3. Market Analysis and Value Proposition 
As outlined above, a system based on infusion via convection-enhanced diffusion 
(CED) shows promise as a delivery method for drugs to allow them to reach 
therapeutic concentrations in a significant volume of the brain.  
This approach however is technically very challenging. Considerable research is 
required to develop tools for the delivery of drugs via catheters placed into the 
solid target tissue.  
The current state of the art is represented by the successful development of a 
software tool to aid the critical step of pre-operative planning of the infusions. 
This has allowed a deeper understanding of the underlying principles to be 
accumulated by the development team.  
Since such knowledge and tools are usually not available within pharmaceutical 
companies, a joint approach is then required to bring the delivery technology, in 
combination with a working drug, to the market.  
This special technological situation combined with the restrictive regulatory 
framework leads to two consecutive use cases: 
 A business-to-business PSS to provide a “one-stop-shop” for 
pharmaceutical companies to manage clinical development and to open up 
the market by getting approval for the drug-device combination 
  A business-to-customer PSS to grow market acceptance once the market 
is opened up by having regulatory approval. 
These two cases are discussed in more detail below. 
The first scenario is required to open up the market for a drug in combination with 
the drug infusion systems.  In such a scenario, the PSS would mainly be focused 
on the “business to business” relationship between the medical device company 
delivering software and hardware tools and the pharmaceutical company 
providing the drug.  
In this scenario, the medical device company has to convince pharmaceutical 
companies of the potential of the technology.  Further, it has to justify, in 
comparison with current practice, any additional risks associated with aspects of 
the treatment such as the required surgery. 
Identifying information gaps for all actors in the market serves as an indicator of 
the issues that need to be addressed by suitable PSS in order to enhance the 
acceptance of the infusion method and create the market. Table 4 shows a list of 
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actors in the market including their generic goals and the main restrictions they 
face.  
Table 4: Actors and their goals and restrictions   
Actor Goal  Restrictions 
Patients  Optimal treatment Training/knowledge of doctors 
Doctors Provision of optimal treatment  Knowledge 
Availability of drugs 
Availability of tools  
Training 
Access to innovative developments 
Pharmaceutical & 
Medical device 
companies 
Profitable provision of drugs and 
medical devices  
Clinical input 
Verification 
Validation 
Reimbursement  
Clinical feedback 
Insurance 
companies 
Cost efficient, safe and effective 
treatment 
Knowledge about technologies 
Availability of cost data (treatment costs 
and cost of care) 
Regulatory 
Authorities 
Safe and effective treatment Knowledge about technologies 
 
After the market is opened up by means of the business-to-business PSS, a second 
“business-to-customer” PSS scenario is required to ensure fast market acceptance 
and market penetration of the drug-device combination.  
The generic value proposition for convection-enhanced delivery, valid for both 
PSS scenarios is to reliably deliver a therapeutic agent to a specific clinical target 
within a patient’s brain. 
In the first, business-to-business PSS, this value proposition offers the 
pharmaceutical company, as the “user” of the system, firstly, all the required tools 
(products) to operate the system successfully (e.g. planning software, reviewing 
software, data management infrastructure) and, secondly, the services (consulting, 
data management, quality assurance, trainings, review processes, on-site support) 
to successfully run a clinical trial, minimizing the risk of trial failure. 
In the business-to-customer PSS, the value proposition is targeted towards the 
neurosurgeon, as the “user” of such a system.  The user can minimize the risks of 
treatment by having available the right tools (e.g. planning software, catheters, 
infusion pumps, etc.)  and services (e.g. training, on-site support, etc.).  
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Creating this market penetration is obviously of value for both providers of the 
drug device combination. 
3.4. Users Analysis  
Based on Morelli’s proposed methodology, the users of both PSS scenarios have 
been analysed. In the business-to-business model, a pharmaceutical company in 
the market of brain tumours would be the customer for the products and services. 
In the second business-to-customer model, the customer would be any 
neurosurgeon who wants to treat brain tumour patients with this specific drug-
device combination. 
Table 5 shows the results of a users analysis for the business-to-business PSS, 
where pharmaceutical companies are the user. 
Table 5: Actors analysis – Pharmaceutical Companies 
Pharmaceutical companies  
Goals Have approved drugs on the market to effectively treat high-grade 
brain tumours.  
Key Problems The blood-brain-barrier (BBB) prevents large molecules from 
entering the brain through the blood cycle.  
Problem solving strategies Circumvent the BBB by directly delivering the therapeutic agent 
to the target tissue within the brain. 
Requirements to be met by the 
problem-solving strategies 
Availability of reliable, easy to use technology for direct drug 
delivery 
Availability of users capable of using the technology 
Current theories Drug distribution within the brain is dependant on patient specific 
anatomy and pathology. 
Tacit knowledge To be effective, the anti cancer agent needs to reach therapeutic 
concentration level within the target volume  
Design methods & criteria  Minimal invasive surgical procedures 
Surgical workflow based on well-known standard procedures 
Intuitive and fast planning of the surgery  
Patient specific planning 
Users’ practice  Pharmaceutical companies are used to perform and manage 
clinical trials without the technological complexity associated with 
local delivery of the drug 
Perceived substitution function Technological complexity of local drug delivery 
Exemplary artefacts - 
 
Table 6 summarizes the analysis of neurosurgeons as the target group for a PSS 
offered, once the market is created and the drug-device combination is available 
for routine clinical use.  
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Table 6: Actors analysis – Neurosurgeons 
Neurosurgeons   
Goals Provide best possible treatment approach 
Be well educated and trained for treatment approach 
Minimize impact of treatment on daily life of patient 
Increase survival rates 
Improve quality of life 
Key Problems Probability of recurrence2 is extremely high 
Prognosis is very poor, independent of the treatment  
Tumour resection
3
 (surgery) is highly invasive  
Radiotherapy has major side effects  
Chemotherapy has minimal effect and major side effects 
Problem solving strategies Direct delivery of therapeutic agent to the tumour and surrounding 
tissue 
Requirements to be met by the 
problem solving strategies 
Reliability of treatment method 
Ease of use of required tools 
Appropriate training  
Appropriate on-site support 
Current theories Drug distribution within the brain is dependant on patient specific 
anatomy and pathology. 
Tacit knowledge Minimal invasive treatment is required 
Design methods & criteria  Minimal invasive surgical procedures 
Surgical workflow based on well-known standard procedures 
Intuitive and fast planning of the surgery  
Patient specific planning 
Users’ practice  Precise placement of biopsy needles in order to take tissue 
samples from a specified target volume within the brain. 
Perceived substitution function - 
Exemplary artefacts - 
 
3.5. Product/Service Definition 
Derived from the users analysis, several service components have been identified 
as crucial for the success of both PSS scenarios (see Table 7). Those services may 
be combined with the product (software tool for treatment planning including a 
simulation of drug distribution within the brain tissue based on patient specific 
imaging data) to multiply the use of the software features. The software may, for 
example, not only be used by neurosurgeons to plan treatments. Reviewers 
auditing neurosurgeons in clinical trials to ensure high compliance to the outlined 
                                                 
2 return of disease after tumour removal  
3 removal of tumour in a surgical procedure 
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trial protocol may also use this tool. Outside the clinical field, the software may 
also be offered in a business-to-business context to help catheter developers in 
their development by simulating different design methods.  Knowledge gathered 
during the development of the product can be directly translated into services to 
capitalize on this knowledge.  
Services may also be tailored to both PSS scenarios. The training of 
neurosurgeons, for example, is required during a trail to minimize failure of the 
trial due to human error, but this is obviously also is of great importance once the 
treatment is available on the market.  
The presentation of such services as training however may change depending on 
the target group. While for a small study, the PSS developers can do the training 
personally, the same training content may have to be provided by a service force 
if a worldwide trial is carried out. To translate this service into the business-to-
customer scenario, with the possibility that any neurosurgeon has to be trained, 
supporting tools such as e-learning modules have to be applied to keep the quality 
of training high. 
 Table 7: Product and service components 
Services Description 
Planning software tool  The planning tool is the technological basis 
for the treatment. It can also be recombined 
with services.  
Clinical trial preparation 
Consulting on CED technologies 
Consulting on trial design 
Consulting on drug selection for CED 
Consulting on patient selection  
Results and expert knowledge gathered 
during R&D (incl. verification and 
validation) can be offered as a consulting 
service. 
This service covers the lack of technological 
expertise regarding CED methods in 
pharmaceutical companies. 
Data management for clinical trials  Software may be used as platform to generate 
compatible data basis for review processes or 
retrospective analysis 
Quality management for clinical trials Software may be used as platform to review 
performance on a patient-by-patient basis. 
This reduces risk of trail failure, since 
corrective measures can be taken during the 
trial. 
Training  
Technological background of CED 
Obtaining useful medical imaging 
Software tool and expert knowledge may be 
used to train all involved persons 
(neurosurgeons, radiologists, nurses) 
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Use of software (catheter planning) 
Placement of catheters (surgical workflow) 
Infusion processes at bed site 
Re-training if required due to results of reviews 
On-site support Use in-house experts trained on software to 
consult with neurosurgeons during the 
planning phase and the surgical procedure 
 
3.6. Use-Case Analysis and PSS Architecture  
Bearing in mind the previously defined product and service components, the two 
basic use-cases have been analysed to design and visualize PSS suitable to 
establish a new market and to maintain and grow such a market afterwards. 
3.6.1. The Business-to-Customer Scenario 
Although chronologically second, the use case for the scenario after the market 
has been created has been analysed first, as the efforts to establishing the market 
may be to no purpose if the method of making the drug delivery route reliable, 
and clinically routine is not designed correctly.  
Figure 2 illustrates a (simplified) clinical workflow for a patient eligible for 
treatment. The figure shows the tools and the environment required as well as the 
clinical staff involved in the process of diagnosis and treatment. Once a patient 
enters the workflow, several diagnostic tests will be conducted. For brain tumour 
patients this will include medical imaging. To acquire these medical images, a 
scanner, and scanner software to process the information, are required.  
The flow of data and the processing has to be integrated into the system to further 
use this information for diagnosis, patient education, treatment planning and 
surgical treatment as well as for retrospective analysis and disease monitoring.  
Once the patient is referred to treatment, the planning software may take available 
data from the diagnostic imaging (additional imaging may be acquired upon 
request) for the treatment planning. A neurosurgeon will then use the software 
tool to plan the treatment based on the patient-specific imaging data to ensure a 
high coverage of the clinical target. The finalized treatment plan can then be 
transferred to the OR, where the  pre-planned catheters are surgically placed  by 
the neurosurgeon.  
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Once the surgical procedure is completed, the infusion of the anti cancer drug will 
be started at the intensive care station. To monitor the treatment outcome, follow-
up scans are performed. The complexity of treatment planning for such drug 
infusion techniques requires additional services, such as training of neurosurgeons 
(to plan and actually place catheters correctly during surgery), radiologists (to 
acquire the right medical images for the treatment planning) and nurses (to 
correctly maintain the infusion).   
As a single component, like a working drug is not sufficient to treat patients and 
therefore generate the safety and efficacy data required for market approval, an 
integrated PSS addressing all these requirements is mandatory to get a drug, 
delivered with a catheter-based infusion technique, onto the market. 
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Figure 2: Visualization of use-case for the business-to-customer PSS
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Looking at this proposed workflow, the required features of products and services 
can be recognised.  
Table 8 lists the key features identified for the planning software in order to 
facilitate the catheter planning and placement process. 
Table 8: Critical product features 
Key software features 
Ease of use / no time consuming planning 
Automatic image analysis 
Outline of clinical targets 
Ability to communicate with hospital data management system (PACS4) 
Ability to fuse (overlay) scans from different time points 
Compatibility with surgical navigation system 
Integration with catheter technology (e.g. consideration of catheter diameter in the planning) 
Integration with pump technology (e.g. consideration of pressure fluctuations caused by the pump) 
 
Additionally, the following service-oriented features have been identified for the 
business-to-customer scenario (see Table 9): 
Table 9: Critical service features for a business-to-customer scenario  
Key service features 
Appropriate knowledge transfer from R&D into clinic 
Training on planning software use 
Consulting on surgical workflow 
Training on catheter handling 
Consulting on integration into hospital IT 
Consulting on protocols for medical imaging required for planning 
Easy access to information for retraining (e.g. web based e-learning tools) 
Availability of on-site support, if required 
Feedback processes to incorporate users feedback in enhanced developments 
 
3.6.2. The Business-to-Business Scenario 
Figure 3 shows a visualization of a use-case scenario
5
 as the basis for the 
business-to-business PSS required in order to obtain approval for clinical use for a 
drug-infusion method combination.  
                                                 
4 Picture Archiving and Communication System (PACS) 
5 based on Morelli 
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A pharmaceutical company developing drugs for brain tumours (or 
neurodegenerative diseases) would have to make decisions about how newly 
developed drugs in the R&D pipeline should be delivered to the clinical target.  
Such a company may also consider further screening of drugs which have been 
previously developed. Of interest would be those drugs where there is clear 
indication of effectiveness, but where the drug failed in previous trials for 
particular sets of reasons.  Where those reasons for failure include the drug failing 
to reach the clinical target, or showing unacceptable side effects when given 
systemically
6
, such drugs may be reconsidered for use in combination with a new 
infusion system. 
This screening process requires an in-depth understanding of underlying 
principles of the infusion mode, which can be offered to a pharmaceutical 
company as a consulting service, using knowledge derived from the knowledge 
base in R&D.  
A significant barrier for pharmaceutical companies to actually use infusion as a 
delivery method for their molecules is that this technology adds to the complexity 
to the treatment and, therefore, also to the setup of a clinical trial. By offering 
services to close gaps of expertise and knowledge, those barriers can be 
eliminated.  
By consulting drug companies on the design of the clinical trial in the planning 
phase and also the management of the trial, risks of trial failure can be mitigated.  
 
                                                 
6 given orally or intravenously  
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Figure 3: Visualization of use-case for the business-to-business PSS
28 
 
 
Table 10: Critical service features for a business-to-business scenario 
Key service features 
Consulting on clinical protocols and procedures 
Availability of training materials 
Data management for clinical trials (especially processing of imaging data) 
Quality management of clinical trials (review and audit processes by means of the planning software as a 
review tool) 
Training on planning software use (for neurosurgeons) 
Training on infusion procedures (for nurses) 
Training on imaging protocols (for radiologists) 
Consulting on surgical workflow (for neurosurgeons) 
Training on catheter handling and placement (for neurosurgeons) 
Easy access to information for retraining (e.g. web based e-learning tools) 
Availability of on-site support, if required 
Analysis of patient data during the trial to minimize risk of trial failure 
Analysis of data in the light of predefined research questions 
Feedback processes to incorporate users feedback in enhanced developments 
 
The analysis of the presented case study suggests that further research on PSS 
applied in the field of health care is required to identify areas where benefits of 
PSS match unmet needs in the health care sector. Subsectors within the health 
care sector will have to be analyzed with regards to potential added benefit by 
means of PSS. In addition, guidelines for designing and implementing PSS in a 
health care market environment have to be developed and validated in order to 
facilitate adoption in the industry.    
 
4 Conclusions 
Product Service Systems in health care have not been in the focus of PSS research 
in the past, although the concept holds great potential to address major challenges 
in this sector.  
The cost explosion and additional cost pressure resulting from globalization is a 
serious threat to the industry also in the health care sector. PSS is a useful tool to 
reduce costs and resources while maximizing the outcome. Companies can 
capitalize on the knowledge they generate during the research and development 
process of a product, by selling this knowledge in separate services. In addition, 
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products may also be reused in combination with several different services. This 
is especially true for software products, which can easily be recombined with 
services to provide additional benefit for a customer group or to exploit new 
markets. 
Due to the high degree of specialization in medical health care and increased 
complexity of technology, integration of technologies, products and services 
becomes a whole field of new service components expected by the customer.  
Products (tools) and information have to be available at the right point and in 
required quality during more complex clinical workflows facing a significant 
increase of actors and interfaces caused by specialization and digitalization of 
patient data. 
PSS offers the chance to establish an extremely close relationship to the user. This 
is of special benefit for developers in the health care sector, since the knowledge 
gap between developers (e.g. engineers or software developers) and physicians is 
generally quite wide. From a company’s perspective PSS creates an access to 
customers as part of the R&D and quality management processes owing to this 
close relationship.  
In a business-to-business scenario, closer relationships can be established between 
business partners. Those business relations are more likely to be of a cooperative 
nature, since PSS ultimately focus on the final benefit for the end user, which 
streamlines efforts of all partners towards the same goal.  This stands in contrast 
to, for example, supply chain thinking, were each participant in the chain tries to 
maximize its revenue on the following company in the chain and in fact may not 
beware of the final customer. Processes can be optimized on a higher level by 
having this common final goal. 
The interdisciplinary approaches required for the success of combinations of drug 
and drug-delivery techniques set a high requirement on communication between 
users and developers. 
Since PSS causes the designer of those systems to focus on the final customer 
need, it is a very helpful tool for strategic considerations. The combination of 
products and services may have the critical mass to establish the market, while a 
product on its own may face too many barriers. Those barriers for a market entry 
can be specifically eliminated with additional services.  In addition, knowledge 
created during the development process can be sold as consulting and training 
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services leading to increased revenue but also creating additional benefit for the 
user.  
Once on the market PSS can increase market acceptance compared to a product 
without supplementary services. Especially in the launch of a PSS, this can lead to 
a broader base of potential customers, for example if services are offered that 
educate customers in using a product that usually would just be used by a small 
group of experts. Additionally, the market penetration can be increased, if services 
and products are designed for an easier user adoption.   
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